Table 1 Subjective changes on lysine aspirin (LAS) treatment
From: Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease
At 3 months | At 12 months | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n = 78 | n = 78 | n = 77 | n = 78 | n = 26 | n = 26 | n = 26 | n = 26 | |||||||||
Asthma | Rhinitis | Nasal polyps | Global | Asthma | Rhinitis | Nasal polyps | Global | |||||||||
Worse | 16 | 21% | 14 | 18% | 24 | 31% | 18 | 23% | 3 | 12% | 8 | 31% | 6 | 23% | 7 | 27% |
Unchanged | 38 | 49% | 43 | 55% | 26 | 34% | 32 | 41% | 10 | 38% | 6 | 23% | 6 | 23% | 4 | 15% |
Better | 24 | 31% | 21 | 27% | 27 | 35% | 28 | 36% | 13 | 50% | 12 | 46% | 14 | 54% | 15 | 58% |
Better or the same | 62 | 79% | 64 | 82% | 53 | 68% | 60 | 77% | 23 | 88% | 18 | 69% | 20 | 77% | 19 | 73% |